DKD. M. Kantieva

D. M. Kantieva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


D. M. Kantieva has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparison of efficacy and tolerability of gemcitabine and gemcitabine plus nab-paclitaxel in 2nd line therapy for pancreatic cancer. Experience of one center

    by Y. E. Chikhareva, Чихарева Я. Е., D. M. Kantieva, Кантиева Д. М., M. S. Manukyan, Манукян М. Ш., A. Y. Kashcheeva, Кащеева А. Ю., A. N. Polyakov, Поляков А. Н., et al.

    Background. First-line therapy for advanced pancreatic cancer often involves combination regimens, including gemcitabine plus nab-paclitaxel (GEM-NAB), whereas the optimal treatment strategy in the second-line setting remains a subject of debate. Aim. To compare efficacy and tolerability of gemcitabine (GEM) monotherapy and GEM-NAB combination as second-line treatment for pancreatic cancer. Materials and methods. This retrospective single-center study was conducted in patients with pancreatic adenocarcinoma receiving second-line chemotherapy with one of two regimens: GEM monotherapy or the GEM-NAB combination. The primary endpoint was overall survival. Secondary endpoints included progression-free survival, objective response rate, disease control rate, and safety. Results. A total of 118 patients were included: 57 received GEM and 61 received GEM-NAB. The groups were comparable in baseline clinical and demographic characteristics. Median follow-up was 9 months. Median OS was 5.9 months (95 % confidence interval (CI) 3.8–8.0) in the GEM group and 6.4 months (95 % CI 4.5–8.3) in the GEM-NAB group (p = 0.772). Median progression-free survival was 3.3 months (95 % CI 2.8–3.8) and 4.7 months (95 % CI 3.6–5.8), respectively (p = 0.079). Objective response rate was 15.8 % and 28.6 %, respectively (p = 0.127). The incidence of grade III–IV adverse events was comparable between the groups. In multivariate analysis, ECOG status ≥ 2, liver metastases, and decreased hemoglobin level were identified as independent predictors of poor survival. Conclusion. Gemcitabine plus nab-paclitaxel combination as 2nd line therapy did not demonstrate statistically significant improvement in overall survival compared with gemcitabine monotherapy and showed a comparable safety profile.

  • Efficacy of mFOLFIRINOX reinduction in locally advanced unresectable and metastatic pancreatic cancer in real clinical practice

    by A. Yu. Kashcheeva, Ya. E. Chikhareva, G. G. Makiev, D. M. Kantieva, M. Sh. Manukyan, I. S. Bazin, A. A. Tryakin

    Pancreatic cancer remains one of the most aggressive malignancies with an unfavorable prognosis. Over 50 % of patients present with distant metastases at initial diagnosis and the five-year overall survival in this cohort does not exceed 3 % [1, 2]. In contemporary clinical practice the combination regimens mFOLFIRINOX and GemNab have become firmly established as first-line therapy standards in both Russian (RUSSCO) and international (ESMO, NCCN) clinical guidelines [3, 4, 5]. However determining the optimal therapeutic approach upon disease progression remains challenging due to limited evidence-based options highlighting the need to explore new treatment strategies including the reinduction of previously used regimens. A single-center retrospective study conducted at the N. N. Blokhin National Medical Research Center of Oncology analyzed data from 31 patients with locally advanced or metastatic pancreatic adenocarcinoma who received mFOLFIRINOX reinduction following a progression-free interval of at least 3 months after first-line chemotherapy. The study assessed progression-free survival during first-line therapy (PFS 1) and reinduction (PFS 2), as well as overall survival from diagnosis (OS) and from reinduction initiation (OS 2). Median PFS 1 was 13 months (95 % CI: 11.6–14.4), and median PFS 2 was 7.0 months (95 % CI: 5.7–8.3). Median OS reached 23.0 months (95 % CI: 18.5–27.5), while median OS 2 was 8.0 months (95 % CI: 6.2–9.8). The toxicity profile upon retreatment was comparable to initial treatment with a trend toward reduced hematologic toxicity likely associated with optimized supportive care. In conclusion the preliminary data from our study demonstrate that the mFOLFIRINOX reintroduction strategy is a promising approach in the treatment of patients with locally advanced and metastatic pancreatic cancer. The results indicate clinically meaningful efficacy of regimen reuse, warranting further investigation of this approach.

  • Selection of drainage method for resectable cholangiocarcinoma complicated by obstructive jaundice

    by A.N. Polyakov, A.G. Kotelnikov, V.I. Egorov, E.R. Virshke, D.YU. Frantsev, O.N. Sergeeva, D.M. Kantieva, D.V. Podluzhny, A.P. Tishchenko

    Objective. To compare the results of percutaneous and endoscopic biliary decompression for resectable perihilar tumor (PT). Material and methods. Treatment outcomes were analyzed in patients with PT who underwent surgery between 1999 and 2023. The 1st group included patients who underwent percutaneous transhepatic cholangiostomy as the first stage for biliary decompression, the 2nd group — patients who underwent endoscopic biliary drainage. Results. There were 58 patients with percutaneous transhepatic cholangiostomy and 18 ones with endoscopic biliary drainage. Both groups were comparable in main parameters. There were patients with isolated resection of extrahepatic bile ducts in the group of percutaneous transhepatic cholangiostomy, but these were absent in the 2nd group (p=0.328). Extended right-sided hemihepatectomies were more common in the 1st group (29.3% versus 11.1%, p=0.210). Post-manipulation complications grade ≥ III degree more common after endoscopic biliary drainage (50.0% versus 22.4%, p=0.037), and percutaneous cholangiostomy was also more common to correct complications (44.4% versus 10.3%, p=0.003). There was no difference in the rate of post-resection complications grade ≥III (p=0.787) and postoperative mortality (p=0.721). There was also no difference in peritoneal metastases (p=1.0) and implantation metastases (p=1.0). In addition, we found no worsening of long-term results after percutaneous transhepatic cholangiostomy. The median overall survival in this group was 25 months versus 15 months after endoscopic biliary drainage (p=0.740). There was also no difference in disease-free survival (p=0.500). Conclusion. Percutaneous transhepatic cholangiostomy as the primary method for obstructive jaundice in patients with resectable PT is accompanied by better immediate results of biliary decompression without worsening the results of resection.

  • Open Access

    Intraoperative indocyanine green lymphography during lymph node dissection in patients with colorectal cancer liver metastases

    by Alina V. Korshak, D. V. Podluzhnyi, А. Г. Котельников, V/ I. Egorov, M G. Abgaryan, M. V. Batalova, G. G. Makiev, A. A. Tryakin, D. M. Kantieva, M. Sh. Manukyan, et al.

    Интраоперационная лимфография с индоцианином зеленым при лимфодиссекции у больных с метастазами колоректального рака в печени

  • Open Access

    Neoadjuvant chemotherapy for resectable intrahepatic cholangiocarcinoma: short-term outcomes

    by A. Sh. Umirzokov, A. V. Korshak, S. N. Korchagina, V. N. Zhuykov, V. I. Egorov, D. M. Kantieva, I. V. Savchenko, A. V. Moiseenko, Aleksandr N. Polyakov

    Background. Neoadjuvant chemotherapy (NACT) is not included in standard treatment protocols for patients with intrahepatic cholangiocarcinoma (ICC). Aim. To compare immediate treatment outcomes in ICC patients receiving NACT versus surgery alone. Materials and methods. The retrospective analysis included patients who underwent surgery for ICC between 2010 and 2024. NACT-related complications were assessed using CTCAE v.5.0, treatment response was evaluated per the RECIST 1.1 criteria, and the impact of NACT on postoperative complications and likelihood of adjuvant chemotherapy (ACT) completion were analyzed. Results. The surgery-only (control) group included 108 patients, while the NACT group included 49 patients. Grade III NACT-related complications developed in 2 (4.4 %) patients. Partial response (PR) to NACT was observed in 5 (10.2 %) patients, with stable disease was achieved in 40 (81.6 %) patients. R0 resection was achieved in 91 (84.3 %) patients in the surgery-only group and 47 (95.9 %) in the NACT group (p = 0.113). NACT did not affect the risk of severe postoperative complications (hazard ratio 0.482; 95 % confidence interval 0.183–1.268; p = 0.139). Patients receiving NACT completed ACT more frequently compared to control group: 76 (70.4 %) versus 43 (87.8 %), respectively (p = 0.026). Conclusion. NACT demonstrated high safety but low PR rates and no impact on R0 resection achievement probability.

  • Combined treatment for locally advanced BRCA1-associated pancreatic cancer: a case report

    by A. Yu. Kashcheeva, A. N. Polyakov, G. G. Makiev, D. M. Kantieva, Yа. E. Chikhareva, I. S. Bazin, Я. Е. Чихарева

    Pancreatic cancer (PC) remains one of the most aggressive malignancies with poor prognosis, particularly in locally advanced and metastatic forms. Germline BRCA1/2 mutations, found in approximately 5 % of PC patients, are associated with increased sensitivity to platinum-based chemotherapy (CT) and PARP inhibitor therapy. This article presents a clinical case of successful combined treatment for locally advanced BRCA1-associated PC. The reported case demonstrates the efficacy of a comprehensive approach incorporating platinum-based CT, irreversible electroporation (IRE), pancreatic resection, stereotactic radiotherapy (RT), and PARP inhibitor targeted therapy in BRCA1-associated PC. The study highlights the crucial importance of molecular genetic testing at initial diagnosis for optimal treatment strategy selection. The findings confirm both the efficacy and safety of prolonged olaparib administration, warranting further investigation of this therapeutic approach in clinical trials.

  • Open Access

    Pancreaticoduodenectomy in multivisceral surgeries: clinical experience of two institutions

    by V. I. Egorov, А. Г. Котельников, Yu. I. Patyutko, D. V. Podluzhny, F. Sh. Akhmetzyanov, D. M. Ruvinsky, N. E. Kudashkin, A. N. Polyakov, D. M. Kantieva, I. S. Bazin, et al.

    Aim. To describe the experience of multivisceral surgeries involving pancreaticoduodenectomy for tumors of various localizations, performed in two Russian medical institutions.Materials and methods. A retrospective study was conducted on the outcomes of 251 multivisceral surgeries with pancreaticoduodenectomy performed in two medical institutions from January 2011 to April 2024.Results. Tumors of pancreatic head, duodenum and large papilla of duodenum were detected in 180 cases (71.7%); colorectal tumors in 36 cases (14.3%); gastric tumors in 24 cases (9.6%); extrahepatic bile duct and gallbladder tumors in 7 cases (2.8%); renal tumors in 3 cases (1.2%); retroperitoneal tumor in 1 case (0.4%). In 107 cases, the surgery was combined with liver resection, including hemihepatectomy in 7 cases. Pancreaticoduodenectomy was combined with colorectal resection in 95 cases. Despite the extreme variability in the extent of multivisceral surgeries with pancreaticoduodenectomy, the complication rate and mortality amounted to 65.7% and 7.2%, respectively.Conclusion. The structure of multivisceral surgeries with pancreaticoduodenectomy appears to be extremely heterogeneous in terms of localization, tumor histogenesis, and the volume of surgical interventions. The frequency of postoperative complications and mortality indicates acceptable tolerability of such surgeries.

  • Open Access

    Pancreatic ductual carcinoma with isolated liver metastases: is it worth performing surgical resection?

    by V. I. Egorov, А. Г. Котельников, D. M. Kantieva, I. S. Bazin

    Pancreatic ductal cancer is one of the most aggressive malignancy with a high incidence of advanced stages at the time of diagnosis and unsatisfactory long-term treatment results. It is believed that pancreatic ductal cancer in the presence of distant metastases identified at the stage of intraoperative revision or before surgery is a contraindication to surgical treatment. There is currently renewed interest in surgical treatment of patients with oligometastatic pancreatic cancer.Material and Methods. The search for sources was carried out in the PubMed and Elibrary systems from January 1995 to January 2024. Of the 1321 sources found, 37 were used to write the review. Data from both retrospective and prospective clinical studies that focused on the results of combined modality treatment of pancreatic cancer with isolated liver metastases were included.Results. To date, a standard treatment strategy for patients with oligometastatic pancreatic cancer has not yet been established; there are no definitive criteria for selecting patients who may benefit from surgical treatment. The current selection criteria for surgery for metastatic pancreatic cancer are far from ideal, extremely heterogeneous and, as a rule, are based only on certain clinical and instrumental data. The starting point for developing selection criteria for surgical treatment of patients with metastatic pancreatic cancer is a common understanding of what “oligometastatic pancreatic cancer” is.

  • Irreversible electroporation in locally advanced pancreatic cancer

    by A.N. Polyakov, Yu.I. Patyutko, N.E. Kudashkin, D.M. Kantieva, K.A. Romanova, E.A. Nasonova, A.V. Korshak, O.A. Egenov, D.V. Podluzhnyi

    ЦЕЛЬ ИССЛЕДОВАНИЯ Определить целесообразность необратимой электропорации (НЭП) при местно-распространенной аденокарциноме поджелудочной железы на основе собственного опыта и данных литературы. МАТЕРИАЛ И МЕТОДЫ С 2015 по 2022 г. 23 пациентам выполнена НЭП по поводу местно-распространенного рака поджелудочной железы после индукционной химиотерапии. НЭП чаще проводили во время лапаротомии (n=22). В 1 случае ее сочетали с паллиативной панкретодуоденальной резекцией. После процедуры адъювантную химиотерапию получили 19 (86,3%) пациентов. Контрольное обследование включало КТ/МРТ брюшной полости с внутривенным контрастированием, рентгенографию или КТ органов грудной клетки, определение опухолевого маркера CA 19-9 через 1 мес после операции, затем каждые 3 мес. РЕЗУЛЬТАТЫ Осложнения после НЭП развились у 5 (21,7%) пациентов. У 3 (13,0%) больных отмечена аритмия, у 3 (8,7%) — панкреонекроз. Девяностодневная летальность после процедуры составила 4,3% (n=1), причина — панкреонекроз. По интраоперационным данным и результатам первого обследования (КТ/МРТ) весь опухолевый инфильтрат был обработан в 21 (91,3%) случае. Медиана времени наблюдения составила 19 мес. Медиана времени до местного рецидива составила 15 мес. Изолированный локальный рецидив наблюдался у 7 больных, 3 из них проведена лучевая терапия, 1 — повторная НЭП. Отдаленные метастазы обнаружены у 11 больных; системная терапия была возобновлена. Медиана времени до прогрессирования составила 7 мес после НЭП и 14 мес после начала индукционной химиотерапии. Медиана общей выживаемости составила 16 мес после электропорации и 25 мес после индукционной химиотерапии. ЗАКЛЮЧЕНИЕ Необратимая электропорация может быть применима у тщательно отобранных пациентов с местно-распространенной аденокарциномой поджелудочной железы после успешной индукционной химиотерапии. Метод обеспечивает локальный контроль, но влияние на отдаленные результаты и целесообразность рутинного использования следует определить в рандомизированных исследованиях.